Media, page-722

Maybe it’s wishful thinking but perhaps a co development deal as was the case recently with Daiichi , may explain the current delay in the Tacti 004 trial.The deciding factor may have been the internal recent data from the head and neck trial which by now would be known by both parties.Mercks expertise in trials along with regular dealings with the FDA and a history of fast patient recruitment would be advantageous to both parties in potentially allowing for the fastest path to market, benefiting both parties.


“The companies will jointly develop and potentially commercialise the drug candidates worldwide, except in Japan, where Daiichi Sankyo will maintain exclusive rights.Daiichi Sankyo will be solely responsible for manufacturing and supply.”


DYOR, purely wishful thinking and speculation on my behalf but perhaps one of many reasons for a current delay in the trial commencement.